|
|
|
þ
|
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the quarterly period ended April 1, 2012
|
|
|
|
o
|
|
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from to
|
NEW JERSEY
(State or other jurisdiction of
incorporation or organization)
|
|
22-1024240
(I.R.S. Employer
Identification No.)
|
Large accelerated filer
þ
|
|
Accelerated filer
o
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
o
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
|
Page
|
|
No.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EX-10.1
|
|
EX-10.2
|
|
EX-10.3
|
|
EX-10.4
|
|
EX-31.1
|
|
EX-32.1
|
|
EX-101 INSTANCE DOCUMENT
|
|
EX-101 SCHEMA DOCUMENT
|
|
EX-101 CALCULATION LINKBASE DOCUMENT
|
|
EX-101 LABELS LINKBASE DOCUMENT
|
|
EX-101 PRESENTATION LINKBASE DOCUMENT
|
|
EX-101 DEFINITION LINKBASE DOCUMENT
|
|
|
April 1, 2012
|
|
January 1, 2012
|
||||
ASSETS
|
||||||||
Current assets:
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
30,267
|
|
|
$
|
24,542
|
|
Marketable securities
|
|
3,580
|
|
|
7,719
|
|
||
Accounts receivable, trade, less allowances for doubtful accounts $419 (2011, $361)
|
|
10,982
|
|
|
10,581
|
|
||
Inventories (Note 2)
|
|
6,800
|
|
|
6,285
|
|
||
Deferred taxes on income
|
|
2,695
|
|
|
2,556
|
|
||
Prepaid expenses and other receivables
|
|
2,683
|
|
|
2,633
|
|
||
Total current assets
|
|
57,007
|
|
|
54,316
|
|
||
Property, plant and equipment at cost
|
|
32,550
|
|
|
31,829
|
|
||
Less: accumulated depreciation
|
|
(17,726
|
)
|
|
(17,090
|
)
|
||
Property, plant and equipment, net
|
|
14,824
|
|
|
14,739
|
|
||
Intangible assets, net (Note 3)
|
|
18,157
|
|
|
18,138
|
|
||
Goodwill, net (Note 3)
|
|
16,339
|
|
|
16,138
|
|
||
Deferred taxes on income
|
|
5,911
|
|
|
6,540
|
|
||
Other assets
|
|
3,956
|
|
|
3,773
|
|
||
Total assets
|
|
$
|
116,194
|
|
|
$
|
113,644
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
|
|
|
|
||||
Loans and notes payable
|
|
$
|
6,439
|
|
|
$
|
6,658
|
|
Accounts payable
|
|
5,085
|
|
|
5,725
|
|
||
Accrued liabilities
|
|
4,369
|
|
|
4,608
|
|
||
Accrued rebates, returns and promotions
|
|
2,865
|
|
|
2,637
|
|
||
Accrued compensation and employee related obligations
|
|
1,526
|
|
|
2,329
|
|
||
Accrued taxes on income
|
|
914
|
|
|
854
|
|
||
Total current liabilities
|
|
21,198
|
|
|
22,811
|
|
||
Long-term debt (Note 4)
|
|
13,010
|
|
|
12,969
|
|
||
Deferred taxes on income
|
|
1,846
|
|
|
1,800
|
|
||
Employee related obligations
|
|
8,236
|
|
|
8,353
|
|
||
Other liabilities
|
|
10,538
|
|
|
10,631
|
|
||
Total liabilities
|
|
54,828
|
|
|
56,564
|
|
||
Shareholders’ equity:
|
|
|
|
|
||||
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)
|
|
$
|
3,120
|
|
|
$
|
3,120
|
|
Accumulated other comprehensive income (Note 7)
|
|
(4,540
|
)
|
|
(5,632
|
)
|
||
Retained earnings
|
|
83,103
|
|
|
81,251
|
|
||
Less: common stock held in treasury, at cost (374,122,000 and 395,480,000 shares)
|
|
20,317
|
|
|
21,659
|
|
||
Total shareholders’ equity
|
|
61,366
|
|
|
57,080
|
|
||
Total liabilities and shareholders' equity
|
|
$
|
116,194
|
|
|
$
|
113,644
|
|
|
|
Fiscal First Quarters Ended
|
||||||||||||
|
|
April 1,
2012 |
|
Percent
to Sales
|
|
April 3,
2011 |
|
Percent
to Sales
|
||||||
Sales to customers (Note 9)
|
|
$
|
16,139
|
|
|
100.0
|
%
|
|
$
|
16,173
|
|
|
100.0
|
%
|
Cost of products sold
|
|
4,915
|
|
|
30.4
|
|
|
4,778
|
|
|
29.5
|
|
||
Gross profit
|
|
11,224
|
|
|
69.6
|
|
|
11,395
|
|
|
70.5
|
|
||
Selling, marketing and administrative expenses
|
|
5,015
|
|
|
31.1
|
|
|
5,056
|
|
|
31.3
|
|
||
Research and development expense
|
|
1,645
|
|
|
10.2
|
|
|
1,738
|
|
|
10.8
|
|
||
Interest income
|
|
(17
|
)
|
|
(0.1
|
)
|
|
(21
|
)
|
|
(0.1
|
)
|
||
Interest expense, net of portion capitalized
|
|
147
|
|
|
0.9
|
|
|
125
|
|
|
0.7
|
|
||
Other (income) expense, net
|
|
(611
|
)
|
|
(3.8
|
)
|
|
(13
|
)
|
|
(0.1
|
)
|
||
Earnings before provision for taxes on income
|
|
5,045
|
|
|
31.3
|
|
|
4,510
|
|
|
27.9
|
|
||
Provision for taxes on income (Note 5)
|
|
1,135
|
|
|
7.1
|
|
|
1,034
|
|
|
6.4
|
|
||
NET EARNINGS
|
|
$
|
3,910
|
|
|
24.2
|
%
|
|
$
|
3,476
|
|
|
21.5
|
%
|
NET EARNINGS PER SHARE (Note 8)
|
|
|
|
|
|
|
|
|
||||||
Basic
|
|
$
|
1.43
|
|
|
|
|
$
|
1.27
|
|
|
|
||
Diluted
|
|
$
|
1.41
|
|
|
|
|
$
|
1.25
|
|
|
|
||
CASH DIVIDENDS PER SHARE
|
|
$
|
0.57
|
|
|
|
|
$
|
0.54
|
|
|
|
||
AVG. SHARES OUTSTANDING
|
|
|
|
|
|
|
|
|
||||||
Basic
|
|
2,736.9
|
|
|
|
|
2,738.4
|
|
|
|
||||
Diluted
|
|
2,774.9
|
|
|
|
|
2,772.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal First Quarters Ended
|
||||||
|
April 1, 2012
|
|
April 3, 2011
|
||||
|
|
|
|
||||
Net Earnings
|
$
|
3,910
|
|
|
$
|
3,476
|
|
|
|
|
|
||||
Other Comprehensive Income (Loss), net of tax
|
|
|
|
||||
Foreign currency translation
|
823
|
|
|
1,373
|
|
||
|
|
|
|
||||
Securities:
|
|
|
|
||||
Unrealized holding gain (loss) arising during period
|
107
|
|
|
113
|
|
||
Reclassifications adjustment for gains included in earnings
|
(1
|
)
|
|
(135
|
)
|
||
Net change
|
106
|
|
|
(22
|
)
|
||
|
|
|
|
||||
Employee benefit plans:
|
|
|
|
||||
Prior service cost amortization during period
|
1
|
|
|
1
|
|
||
Gain (loss) amortization during period
|
93
|
|
|
71
|
|
||
Net change
|
94
|
|
|
72
|
|
||
|
|
|
|
||||
Derivatives & hedges:
|
|
|
|
||||
Unrealized gain (loss) arising during period
|
26
|
|
|
10
|
|
||
Reclassifications to earnings
|
43
|
|
|
78
|
|
||
Net change
|
69
|
|
|
88
|
|
||
|
|
|
|
||||
Other Comprehensive Income (Loss)
|
1,092
|
|
|
1,511
|
|
||
|
|
|
|
||||
Comprehensive Income
|
$
|
5,002
|
|
|
$
|
4,987
|
|
|
|
|
|
The tax effects in other comprehensive income for the fiscal first quarters were as follows for 2012 and 2011 respectively: Securities; $57 million and $12 million, Employee Benefits; $49 million and $39 million, Derivatives & Hedges; $37 million and $48 million. Foreign currency translation is not adjusted for income taxes as it relates to permanent investments in international subsidiaries.
|
|
|
Fiscal Three Months Ended
|
||||||
|
|
April 1,
2012 |
|
April 3,
2011 |
||||
CASH FLOW FROM OPERATING ACTIVITIES
|
|
|
|
|
||||
Net earnings
|
|
$
|
3,910
|
|
|
$
|
3,476
|
|
Adjustments to reconcile net earnings to cash flows from operating activities:
|
|
|
|
|
||||
Depreciation and amortization of property and intangibles
|
|
773
|
|
|
755
|
|
||
Stock based compensation
|
|
173
|
|
|
152
|
|
||
Deferred tax provision
|
|
557
|
|
|
(4
|
)
|
||
Accounts receivable allowances
|
|
42
|
|
|
(16
|
)
|
||
Changes in assets and liabilities, net of effects from acquisitions:
|
|
|
|
|
||||
Increase in accounts receivable
|
|
(215
|
)
|
|
(609
|
)
|
||
Increase in inventories
|
|
(449
|
)
|
|
(452
|
)
|
||
Decrease in accounts payable and accrued liabilities
|
|
(1,331
|
)
|
|
(1,127
|
)
|
||
Increase in other current and non-current assets
|
|
(754
|
)
|
|
(970
|
)
|
||
Increase in other current and non-current liabilities
|
|
89
|
|
|
1,111
|
|
||
|
|
|
|
|
||||
NET CASH FLOWS FROM OPERATING ACTIVITIES
|
|
2,795
|
|
|
2,316
|
|
||
|
|
|
|
|
||||
CASH FLOWS FROM INVESTING ACTIVITIES
|
|
|
|
|
||||
Additions to property, plant and equipment
|
|
(502
|
)
|
|
(436
|
)
|
||
Proceeds from the disposal of assets
|
|
358
|
|
|
121
|
|
||
Acquisitions, net of cash acquired
|
|
—
|
|
|
(2,049
|
)
|
||
Purchases of investments
|
|
(2,398
|
)
|
|
(1,036
|
)
|
||
Sales of investments
|
|
6,600
|
|
|
4,897
|
|
||
Other
|
|
(2
|
)
|
|
(57
|
)
|
||
|
|
|
|
|
||||
NET CASH FLOWS FROM INVESTING ACTIVITIES
|
|
4,056
|
|
|
1,440
|
|
||
|
|
|
|
|
||||
CASH FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
||||
Dividends to shareholders
|
|
(1,565
|
)
|
|
(1,480
|
)
|
||
Repurchase of common stock
|
|
(67
|
)
|
|
(435
|
)
|
||
Proceeds from short-term debt
|
|
1,547
|
|
|
3,644
|
|
||
Retirement of short-term debt
|
|
(1,790
|
)
|
|
(2,744
|
)
|
||
Proceeds from long-term debt
|
|
2
|
|
|
8
|
|
||
Retirement of long-term debt
|
|
(30
|
)
|
|
(3
|
)
|
||
Proceeds from the exercise of stock options/excess tax benefits
|
|
880
|
|
|
185
|
|
||
Other
|
|
(160
|
)
|
|
—
|
|
||
|
|
|
|
|
||||
NET CASH USED BY FINANCING ACTIVITIES
|
|
(1,183
|
)
|
|
(825
|
)
|
||
|
|
|
|
|
||||
Effect of exchange rate changes on cash and cash equivalents
|
|
57
|
|
|
70
|
|
||
Increase in cash and cash equivalents
|
|
5,725
|
|
|
3,001
|
|
||
Cash and Cash equivalents, beginning of period
|
|
24,542
|
|
|
19,355
|
|
||
CASH AND CASH EQUIVALENTS, END OF PERIOD
|
|
$
|
30,267
|
|
|
$
|
22,356
|
|
Acquisitions
|
|
|
|
|
||||
Fair value of assets acquired
|
|
$
|
—
|
|
|
$
|
2,245
|
|
Fair value of liabilities assumed and non-controlling interests
|
|
—
|
|
|
(196
|
)
|
||
Net cash paid for acquisitions
|
|
$
|
—
|
|
|
$
|
2,049
|
|
(Dollars in Millions)
|
|
April 1, 2012
|
|
January 1, 2012
|
|||
Raw materials and supplies
|
|
$
|
1,428
|
|
|
1,206
|
|
Goods in process
|
|
1,798
|
|
|
1,637
|
|
|
Finished goods
|
|
3,574
|
|
|
3,442
|
|
|
Total inventories
|
|
$
|
6,800
|
|
|
6,285
|
|
(Dollars in Millions)
|
|
April 1, 2012
|
|
January 1, 2012
|
|||
Intangible assets with definite lives:
|
|
|
|
|
|||
Patents and trademarks — gross
|
|
$
|
8,130
|
|
|
7,947
|
|
Less accumulated amortization
|
|
3,122
|
|
|
2,976
|
|
|
Patents and trademarks — net
|
|
5,008
|
|
|
4,971
|
|
|
Other intangibles — gross
|
|
8,668
|
|
|
8,716
|
|
|
Less accumulated amortization
|
|
3,517
|
|
|
3,432
|
|
|
Other intangibles — net
|
|
5,151
|
|
|
5,284
|
|
|
Intangible assets with indefinite lives:
|
|
|
|
|
|||
Trademarks
|
|
6,118
|
|
|
6,034
|
|
|
Purchased in-process research and development
|
|
1,880
|
|
|
1,849
|
|
|
Total intangible assets with indefinite lives
|
|
7,998
|
|
|
7,883
|
|
|
Total intangible assets — net
|
|
$
|
18,157
|
|
|
18,138
|
|
(Dollars in Millions)
|
|
Consumer
|
|
Pharm
|
|
Med Dev & Diag
|
|
Total
|
|||||
Goodwill, net at January 1, 2012
|
|
$
|
8,298
|
|
|
1,721
|
|
|
6,119
|
|
|
16,138
|
|
Acquisitions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Currency translation/Other
|
|
172
|
|
|
21
|
|
|
8
|
|
|
201
|
|
|
Goodwill, net as of April 1, 2012
|
|
$
|
8,470
|
|
|
1,742
|
|
|
6,127
|
|
|
16,339
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
Gain/ (Loss)
recognized in
Accumulated
OCI
(1)
|
|
Gain/(Loss) reclassified from
Accumulated OCI
into income
(1)
|
|
Gain/ (Loss)
recognized in
Other
income/expense
(2)
|
|||||||||||||
|
|
Fiscal First Quarters Ended
|
|||||||||||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|||||||
Cash Flow Hedges by Income Statement Caption
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Sales to customers
(A)
|
|
$
|
28
|
|
|
27
|
|
|
(20
|
)
|
|
(10
|
)
|
|
1
|
|
|
(2
|
)
|
Cost of products sold
(A)
|
|
58
|
|
|
80
|
|
|
(21
|
)
|
|
(62
|
)
|
|
(1
|
)
|
|
(3
|
)
|
|
Research and development expense
(A)
|
|
(19
|
)
|
|
(36
|
)
|
|
2
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
Interest (income)/Interest expense, net
(B)
|
|
(1
|
)
|
|
(9
|
)
|
|
(3
|
)
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
|
Other (income)expense, net
(A)
|
|
(40
|
)
|
|
(52
|
)
|
|
(1
|
)
|
|
(5
|
)
|
|
—
|
|
|
2
|
|
|
Total
|
|
$
|
26
|
|
|
10
|
|
|
(43
|
)
|
|
(78
|
)
|
|
—
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
April 1, 2012
|
|
|
|
January 1, 2012
|
||||||||||
(Dollars in Millions)
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Total
(1)
|
||||||
Derivatives designated as hedging instruments:
|
|
|
|
|
|
|
|
|
|
|
||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign exchange contracts
|
|
$
|
—
|
|
|
241
|
|
|
—
|
|
|
241
|
|
|
442
|
|
Cross currency interest rate swaps
(2)
|
|
—
|
|
|
8
|
|
|
—
|
|
|
8
|
|
|
15
|
|
|
Total
|
|
—
|
|
|
249
|
|
|
—
|
|
|
249
|
|
|
457
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign exchange contracts
|
|
—
|
|
|
290
|
|
|
—
|
|
|
290
|
|
|
452
|
|
|
Cross currency interest rate swaps
(3)
|
|
—
|
|
|
537
|
|
|
—
|
|
|
537
|
|
|
594
|
|
|
Total
|
|
—
|
|
|
827
|
|
|
—
|
|
|
827
|
|
|
1,046
|
|
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
|
|
|
|
|
|
||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign exchange contracts
|
|
—
|
|
|
23
|
|
|
—
|
|
|
23
|
|
|
29
|
|
|
Swiss Franc Option*
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
17
|
|
|
Total
|
|
—
|
|
|
23
|
|
|
—
|
|
|
23
|
|
|
46
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign exchange contracts
|
|
—
|
|
|
19
|
|
|
—
|
|
|
19
|
|
|
34
|
|
|
Other Investments
(4)
|
|
$
|
1,739
|
|
|
—
|
|
|
—
|
|
|
1,739
|
|
|
1,563
|
|
(1)
|
As of January 1, 2012, these assets and liabilities are classified as Level 2 with the exception of Other Investments of $
1,563 million
which are classified as Level 1.
|
(2)
|
Includes
$6 million
and
$15 million
of non-current assets for April 1, 2012 and January 1, 2012, respectively.
|
(3)
|
Includes
$536 million
and
$594 million
of non-current liabilities for April 1, 2012 and January 1, 2012, respectively.
|
(4)
|
Classified as non-current other assets.
|
|
|
Retirement Plans
|
|
Other Benefit Plans
|
|||||||||
|
|
Fiscal First Quarters Ended
|
|||||||||||
(Dollars in Millions)
|
|
April 1, 2012
|
|
April 3, 2011
|
|
April 1, 2012
|
|
April 3, 2011
|
|||||
Service cost
|
|
$
|
161
|
|
|
143
|
|
|
44
|
|
|
37
|
|
Interest cost
|
|
222
|
|
|
213
|
|
|
41
|
|
|
48
|
|
|
Expected return on plan assets
|
|
(312
|
)
|
|
(278
|
)
|
|
(1
|
)
|
|
—
|
|
|
Amortization of prior service cost/(credit)
|
|
2
|
|
|
3
|
|
|
(1
|
)
|
|
(1
|
)
|
|
Recognized actuarial losses
|
|
124
|
|
|
96
|
|
|
18
|
|
|
11
|
|
|
Curtailments and settlements
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Net periodic benefit cost
|
|
$
|
196
|
|
|
177
|
|
|
101
|
|
|
95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Foreign
|
|
Securities
|
|
Employee
|
|
Derivatives
|
|
Total Accumulated
|
||||||
Gains/(Losses)
|
|
Currency
|
|
Available
|
|
Benefit
|
|
&
|
|
Other Comprehensive
|
||||||
(Dollars in Millions)
|
|
Translation
|
|
For Sale
|
|
Plans
|
|
Hedges
|
|
Income/(Loss)
|
||||||
January 1, 2012
|
|
$
|
(1,526
|
)
|
|
448
|
|
|
(4,386
|
)
|
|
(168
|
)
|
|
(5,632
|
)
|
Net change
|
|
823
|
|
|
106
|
|
|
94
|
|
|
69
|
|
|
1,092
|
|
|
April 1, 2012
|
|
$
|
(703
|
)
|
|
554
|
|
|
(4,292
|
)
|
|
(99
|
)
|
|
(4,540
|
)
|
|
|
Fiscal First Quarters Ended
|
||||||
(Shares in Millions)
|
|
April 1, 2012
|
|
April 3, 2011
|
||||
Basic net earnings per share
|
|
$
|
1.43
|
|
|
$
|
1.27
|
|
Average shares outstanding — basic
|
|
2,736.9
|
|
|
2,738.4
|
|
||
Potential shares exercisable under stock option plans
|
|
152.2
|
|
|
138.5
|
|
||
Less: shares which could be repurchased under treasury stock method
|
|
(117.8
|
)
|
|
(107.8
|
)
|
||
Convertible debt shares
|
|
3.6
|
|
|
3.6
|
|
||
Average shares outstanding — diluted
|
|
2,774.9
|
|
|
2,772.7
|
|
||
Diluted earnings per share
|
|
$
|
1.41
|
|
|
$
|
1.25
|
|
|
|
|
|
|
|
|
Fiscal First Quarters Ended
|
|||||||||
(Dollars in Millions)
|
|
April 1,
2012 |
|
April 3,
2011 |
|
Percent
Change
|
|||||
|
|
|
|
|
|
|
|||||
Consumer
|
|
|
|
|
|
|
|||||
United States
|
|
$
|
1,316
|
|
|
$
|
1,345
|
|
|
(2.2
|
)%
|
International
|
|
2,279
|
|
|
2,337
|
|
|
(2.5
|
)
|
||
Total
|
|
3,595
|
|
|
3,682
|
|
|
(2.4
|
)
|
||
Pharmaceutical
|
|
|
|
|
|
|
|||||
United States
|
|
3,026
|
|
|
3,391
|
|
|
(10.8
|
)
|
||
International
|
|
3,107
|
|
|
2,668
|
|
|
16.5
|
|
||
Total
|
|
6,133
|
|
|
6,059
|
|
|
1.2
|
|
||
Medical Devices & Diagnostics
|
|
|
|
|
|
|
|||||
United States
|
|
2,877
|
|
|
2,872
|
|
|
0.2
|
|
||
International
|
|
3,534
|
|
|
3,560
|
|
|
(0.7
|
)
|
||
Total
|
|
6,411
|
|
|
6,432
|
|
|
(0.3
|
)
|
||
Worldwide
|
|
|
|
|
|
|
|||||
United States
|
|
7,219
|
|
|
7,608
|
|
|
(5.1
|
)
|
||
International
|
|
8,920
|
|
|
8,565
|
|
|
4.1
|
|
||
Total
|
|
$
|
16,139
|
|
|
$
|
16,173
|
|
|
(0.2
|
)%
|
|
|
|
|
|
|
|
|
|
Fiscal First Quarters Ended
|
|||||||||
(Dollars in Millions)
|
|
April 1,
2012 |
|
April 3,
2011 |
|
Percent
Change
|
|||||
Consumer
|
|
$
|
463
|
|
|
$
|
573
|
|
|
(19.2
|
)%
|
Pharmaceutical
(1)
|
|
2,586
|
|
|
2,209
|
|
|
17.1
|
|
||
Medical Devices & Diagnostics
(2)
|
|
2,081
|
|
|
1,944
|
|
|
7.0
|
|
||
Segments operating profit
|
|
5,130
|
|
|
4,726
|
|
|
8.5
|
|
||
Expense not allocated to segments
(3)
|
|
(85
|
)
|
|
(216
|
)
|
|
|
|||
Worldwide income before taxes
|
|
$
|
5,045
|
|
|
$
|
4,510
|
|
|
11.9
|
%
|
|
|
|
|
|
|
|
(1)
|
Includes litigation expense of
$250 million
in the fiscal first quarter of 2011.
|
(2)
|
Includes
$31 million
of costs associated with the planned acquisition of Synthes, Inc. recorded in the fiscal first quarter of 2012. Includes litigation expense and DePuy ASR™ Hip recall costs of
$96 million
recorded in the fiscal first quarter of 2011.
|
(3)
|
Amounts not allocated to segments include interest income/(expense), non-controlling interests and
general corporate income/(expense). Included in the fiscal first quarter of 2012, was
a
$148 million
currency adjustment associated with the planned acquisition of Synthes, Inc.
|
|
|
Fiscal First Quarters Ended
|
|||||||||
(Dollars in Millions)
|
|
April 1, 2012
|
|
April 3, 2011
|
|
Percent
Change
|
|||||
United States
|
|
$
|
7,219
|
|
|
$
|
7,608
|
|
|
(5.1
|
)%
|
Europe
|
|
4,194
|
|
|
4,183
|
|
|
0.3
|
|
||
Western Hemisphere, excluding U.S.
|
|
1,714
|
|
|
1,436
|
|
|
19.4
|
|
||
Asia-Pacific, Africa
|
|
3,012
|
|
|
2,946
|
|
|
2.2
|
|
||
Total
|
|
$
|
16,139
|
|
|
$
|
16,173
|
|
|
(0.2
|
)%
|
|
|
|
|
|
|
|
(Dollars in Millions)
|
|
April 1, 2012
|
|
April 3, 2011
|
|
Total
Change
|
|
Operations
Change
|
|
Currency
Change
|
|||||||
OTC Pharm. & Nutritionals
|
|
$
|
1,104
|
|
|
$
|
1,129
|
|
|
(2.2
|
)%
|
|
(0.3
|
)%
|
|
(1.9
|
)%
|
Skin Care
|
|
907
|
|
|
899
|
|
|
0.9
|
|
|
2.1
|
|
|
(1.2
|
)
|
||
Baby Care
|
|
540
|
|
|
561
|
|
|
(3.7
|
)
|
|
(1.4
|
)
|
|
(2.3
|
)
|
||
Women’s Health
|
|
409
|
|
|
459
|
|
|
(10.9
|
)
|
|
(8.2
|
)
|
|
(2.7
|
)
|
||
Oral Care
|
|
387
|
|
|
391
|
|
|
(1.0
|
)
|
|
0.7
|
|
|
(1.7
|
)
|
||
Wound Care/Other
|
|
248
|
|
|
243
|
|
|
2.1
|
|
|
3.3
|
|
|
(1.2
|
)
|
||
Total Consumer Sales
|
|
$
|
3,595
|
|
|
$
|
3,682
|
|
|
(2.4
|
)%
|
|
(0.6
|
)%
|
|
(1.8
|
)%
|
(Dollars in Millions)
|
|
April 1, 2012
|
|
April 3, 2011
|
|
Total
Change
|
|
Operations
Change
|
|
Currency
Change
|
|||||||
Total Immunology
|
|
$
|
1,895
|
|
|
$
|
1,580
|
|
|
19.9
|
%
|
|
20.5
|
%
|
|
(0.6
|
)%
|
REMICADE
®
|
|
1,521
|
|
|
1,285
|
|
|
18.4
|
|
|
18.4
|
|
|
0.0
|
|
||
SIMPONI
®
|
|
116
|
|
|
95
|
|
|
22.1
|
|
|
22.6
|
|
|
(0.5
|
)
|
||
STELARA
®
|
|
221
|
|
|
166
|
|
|
33.1
|
|
|
34.8
|
|
|
(1.7
|
)
|
||
Other Immunology
|
|
37
|
|
|
34
|
|
|
8.8
|
|
|
10.7
|
|
|
(1.9
|
)
|
||
Total Infectious Diseases
|
|
755
|
|
|
931
|
|
|
(18.9
|
)
|
|
(17.0
|
)
|
|
(1.9
|
)
|
||
INTELENCE
®
|
|
80
|
|
|
69
|
|
|
15.9
|
|
|
17.8
|
|
|
(1.9
|
)
|
||
LEVAQUIN
®
/FLOXIN
®
|
|
29
|
|
|
434
|
|
|
(93.3
|
)
|
|
(93.2
|
)
|
|
(0.1
|
)
|
||
PREZISTA
®
|
|
324
|
|
|
266
|
|
|
21.8
|
|
|
24.1
|
|
|
(2.3
|
)
|
||
Other Infectious Diseases
|
|
322
|
|
|
162
|
|
|
98.8
|
|
|
**
|
|
(3.0
|
)
|
|||
Total Neuroscience
|
|
1,647
|
|
|
1,745
|
|
|
(5.6
|
)
|
|
(4.3
|
)
|
|
(1.3
|
)
|
||
CONCERTA
®
/methylphenidate
|
|
308
|
|
|
362
|
|
|
(14.9
|
)
|
|
(14.0
|
)
|
|
(0.9
|
)
|
||
INVEGA
®
|
|
121
|
|
|
120
|
|
|
0.8
|
|
|
1.5
|
|
|
(0.7
|
)
|
||
INVEGA
®
SUSTENNA
®
|
|
161
|
|
|
65
|
|
|
**
|
|
**
|
|
—
|
|
||||
RISPERDAL
®
CONSTA
®
|
|
361
|
|
|
404
|
|
|
(10.6
|
)
|
|
(8.7
|
)
|
|
(1.9
|
)
|
||
Other Neuroscience
|
|
696
|
|
|
794
|
|
|
(12.3
|
)
|
|
(11.2
|
)
|
|
(1.1
|
)
|
||
Total Oncology
|
|
596
|
|
|
439
|
|
|
35.8
|
|
|
38.5
|
|
|
(2.7
|
)
|
||
DOXIL
®
/CAELYX
®
|
|
24
|
|
|
139
|
|
|
(82.7
|
)
|
|
(82.1
|
)
|
|
(0.6
|
)
|
||
VELCADE
®
|
|
353
|
|
|
280
|
|
|
26.1
|
|
|
29.3
|
|
|
(3.2
|
)
|
||
ZYTIGA
®
|
|
200
|
|
|
5
|
|
|
**
|
|
**
|
|
(1.9
|
)
|
||||
Other Oncology
|
|
19
|
|
|
15
|
|
|
26.7
|
|
|
29.7
|
|
|
(3.0
|
)
|
||
Total Other
|
|
1,240
|
|
|
1,364
|
|
|
(9.1
|
)
|
|
(7.9
|
)
|
|
(1.2
|
)
|
||
ACIPHEX
®
/PARIET
®
|
|
222
|
|
|
239
|
|
|
(7.1
|
)
|
|
(5.4
|
)
|
|
(1.7
|
)
|
||
PROCRIT
®
/EPREX
®
|
|
376
|
|
|
397
|
|
|
(5.3
|
)
|
|
(3.8
|
)
|
|
(1.5
|
)
|
||
Other
|
|
642
|
|
|
728
|
|
|
(11.8
|
)
|
|
(11.0
|
)
|
|
(0.8
|
)
|
||
Total Pharmaceutical Sales
|
|
$
|
6,133
|
|
|
$
|
6,059
|
|
|
1.2
|
%
|
|
2.6
|
%
|
|
(1.4
|
)%
|
(Dollars in Millions)
|
|
April 1, 2012
|
|
April 3, 2011
|
|
Total
Change
|
|
Operations
Change
|
|
Currency
Change
|
|||||||
General Surgery
|
|
$
|
1,625
|
|
|
$
|
1,621
|
|
|
0.2
|
%
|
|
1.4
|
%
|
|
(1.2
|
)%
|
Orthopaedics
|
|
1,493
|
|
|
1,503
|
|
|
(0.7
|
)
|
|
0.0
|
|
|
(0.7
|
)
|
||
Vision Care
|
|
757
|
|
|
722
|
|
|
4.8
|
|
|
4.5
|
|
|
0.3
|
|
||
Diabetes Care
|
|
670
|
|
|
637
|
|
|
5.2
|
|
|
6.6
|
|
|
(1.4
|
)
|
||
Specialty Surgery
|
|
628
|
|
|
577
|
|
|
8.8
|
|
|
9.9
|
|
|
(1.1
|
)
|
||
Diagnostics
|
|
512
|
|
|
521
|
|
|
(1.7
|
)
|
|
(1.1
|
)
|
|
(0.6
|
)
|
||
Cardiovascular Care
|
|
482
|
|
|
635
|
|
|
(24.1
|
)
|
|
(23.5
|
)
|
|
(0.6
|
)
|
||
Infection Prevention/Other
|
|
244
|
|
|
216
|
|
|
13.0
|
|
|
13.4
|
|
|
(0.4
|
)
|
||
Total Medical Devices and Diagnostics Sales
|
|
$
|
6,411
|
|
|
$
|
6,432
|
|
|
(0.3
|
)%
|
|
0.5
|
%
|
|
(0.8
|
)%
|
|
|
Total Number
of Shares Purchased
|
|
Average
Price Paid per Share
|
|||
Fiscal Month
|
|
|
|
|
|||
January 2, 2012 through January 29, 2012
|
|
251,491
|
|
|
$
|
65.04
|
|
January 30, 2012 through February 26, 2012
|
|
188,471
|
|
|
$
|
64.62
|
|
February 27, 2012 through April 1, 2012
|
|
602,165
|
|
|
$
|
64.63
|
|
Total
|
|
1,042,127
|
|
|
|
|
JOHNSON & JOHNSON
(Registrant)
|
|
|
Date: May 7, 2012
|
By /s/ D. J. CARUSO
|
|
D. J. CARUSO
|
|
Vice President, Finance; Chief Financial Officer (Principal Financial Officer)
|
|
|
Date: May 7, 2012
|
By /s/ S. J. COSGROVE
|
|
S. J. COSGROVE
|
|
Controller (Principal Accounting Officer)
|
WWID #
|
|
Total Shares:
|
Vesting Date:
|
|
Purchase Price:
|
Grant No.
|
Grant Type
|
No. of Shares
|
|
NQSO
|
|
WWID #
|
|
Total Units:
|
Grant Date:
|
|
Vesting Date:
|
Grant No.
|
Grant Type
|
No. of Units
|
|
Restricted Share Units
|
|
WWID #
|
|
Target Number of Units:
|
|
Grant Date:
|
|
Performance Period:
|
|
Vesting Date:
|
The third anniversary of the Grant Date
|
||
Certification Date:
|
The date following the end of the Performance Period on which the Committee certifies the achievement of all remaining performance-based vesting criteria, the achievement of which has not yet been certified, as set forth in
Appendix A
hereto
|
Grant No.
|
Grant Type
|
Target No. of Units
|
|
Performance Share Units
|
|
|
/s/ Alex Gorsky
|
|
Alex Gorsky
|
|
Chief Executive Officer
|
|
|
|
|
|
/s/ Dominic J. Caruso
|
|
Dominic J. Caruso
|
|
Chief Financial Officer
|
|
|
(1)
|
the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 1, 2012 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
/s/ Alex Gorsky
|
|
Alex Gorsky
|
|
Chief Executive Officer
|
|
|
(1)
|
the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 1, 2012 (the “Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
/s/ Dominic J. Caruso
|
|
Dominic J. Caruso
|
|
Chief Financial Officer
|
|
|